Intranasal treatment with bacteriophage rescues mice from Acinetobacter baumannii-mediated pneumonia. (May 2016)

• Record Type: Journal Article
• Authors: Wang, Yong; Mi, Zhiqiang; Niu, Wenkai; An, Xiaoping; Yuan, Xin; Liu, Huiying; Li, Puyuan; Liu, Yannan; Feng, Yuzhong; Huang, Yong; Zhang, Xianglilan; Zhang, Zhiyi; Fan, Hang; Peng, Fan; Tong, Yigang; Bai, Changqing
• Is Part Of: Future microbiology. Volume 11:Number 5(2016:May)
• Page Start: 631
• Page End: 641
• Publication Date: 2016-05
• Subjects: Acinetobacter baumannii -- antibody -- bacteriophage -- cyclophosphamide -- mouse model -- pneumonia; Microbiology -- Research -- Periodicals; 616.9041
• DOI: 10.2217/fmb.16.11
• Languages: English
• ISSNs: 1746-0913

Abstract

Aim: With the emergence of drug-resistant bacteria, finding alternative agents to treat antibiotic-resistant bacterial infections is imperative.Materials & methods: A mouse pneumonia model was developed by combining cyclophosphamide pretreatment and Acinetobacter baumannii challenge, and a lytic bacteriophage was evaluated for its therapeutic efficacy in this model by examining the survival rate, bacterial load in the lung and lung pathology.Results: Intranasal instillation with bacteriophage rescued 100% of mice following lethal challenge with A. baumannii . Phage treatment reduced bacterial load in the lung. Microcomputed tomography indicated a reduction in lung inflammation in mice given phage.Conclusion: This research demonstrates that intranasal application of bacteriophage is viable, and could provide complete protection from pneumonia caused by A. baumannii .